These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 18486526

  • 21. Pharmacogenetics of paclitaxel metabolism.
    Spratlin J, Sawyer MB.
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):222-9. PubMed ID: 17092739
    [Abstract] [Full Text] [Related]

  • 22. [Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping].
    Johansen PW, Bergan S, Rootwelt H, Kvittingen EA, Rugstad HE.
    Tidsskr Nor Laegeforen; 2002 Nov 30; 122(29):2781-3. PubMed ID: 12523145
    [Abstract] [Full Text] [Related]

  • 23. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M, Petrovic N.
    Curr Opin Mol Ther; 2006 Dec 30; 8(6):480-6. PubMed ID: 17243482
    [Abstract] [Full Text] [Related]

  • 24. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y.
    Gan To Kagaku Ryoho; 2003 Mar 30; 30(3):325-33. PubMed ID: 12669388
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Pharmacogenetic testing: soon before every prescription?].
    Buclin T, Colombo S, Biollaz J.
    Rev Med Suisse; 2008 Jul 16; 4(165):1666-70. PubMed ID: 18767293
    [Abstract] [Full Text] [Related]

  • 28. Pharmacogenetics and personalized medicine: the future for drug prescribing.
    Mitri Z, Esmerian MO, Simaan JA, Sabra R, Zgheib NK.
    J Med Liban; 2010 Jul 16; 58(2):101-4. PubMed ID: 20549897
    [Abstract] [Full Text] [Related]

  • 29. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J, Grundmann M.
    Ceska Slov Farm; 2011 Jun 16; 60(3):110-5. PubMed ID: 21838140
    [Abstract] [Full Text] [Related]

  • 30. [Customized drug therapy--how near is the goal?].
    Spigset O.
    Tidsskr Nor Laegeforen; 2006 Sep 21; 126(18):2390-6. PubMed ID: 16998553
    [Abstract] [Full Text] [Related]

  • 31. Pharmacogenomics of colorectal cancer prevention and treatment.
    Nguyen H, Tran A, Lipkin S, Fruehauf JP.
    Cancer Invest; 2006 Oct 21; 24(6):630-9. PubMed ID: 16982469
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs.
    Anderson GD.
    Ther Drug Monit; 2008 Apr 21; 30(2):173-80. PubMed ID: 18367977
    [Abstract] [Full Text] [Related]

  • 33. Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy.
    Mladosievicova B, Carter A, Kristova V.
    Neoplasma; 2007 Apr 21; 54(3):181-8. PubMed ID: 17447847
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T, Price A.
    Am Fam Physician; 2007 Aug 01; 76(3):391-6. PubMed ID: 17708140
    [Abstract] [Full Text] [Related]

  • 36. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P, Waxman DJ.
    Toxicol In Vitro; 2006 Mar 01; 20(2):176-86. PubMed ID: 16293390
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.
    Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M.
    Pharmacopsychiatry; 2003 Nov 01; 36 Suppl 3():S235-43. PubMed ID: 14677085
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.